Stockscreener 앱 받기
144.92
3.19%
-4.5342
전일 마감가:
$149.45
열려 있는:
$148.39
하루 거래량:
578.44K
Relative Volume:
0.67
시가총액:
$7.12B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
18.09
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
-7.84%
1개월 성능:
-11.79%
6개월 성능:
-10.33%
1년 성능:
-25.00%
1일 변동 폭
$144.26
$148.39
1주일 범위
$144.26
$157.95
52주 변동 폭
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
144.66 | 7.36B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
458.70 | 176.72B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
181.05 | 133.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
617.97 | 50.18B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.42 | 35.26B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
176.24 | 30.81B | 15.70B | 1.24B | 2.01B | 6.91 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Riverbridge Partners LLC Has $20.28 Million Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Assenagon Asset Management S.A. Acquires 11,408 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Pharmaceutical Contract Research Services Market Report 2025-2035: M&A, Partnerships, and Biologics Focus - GlobeNewswire Inc.
Is Charles River Laboratories Stock Underperforming The Nasdaq? - Barchart.com
Research Analysts Issue Forecasts for CRL Q3 Earnings - MarketBeat
Charles River Laboratories International (NYSE:CRL) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat
Charles River Laboratories (CRL): Valuation Perspectives After CFO Transition, Guidance Reaffirmation, and New Oncology Partnerships - simplywall.st
Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $177.07 - MarketBeat
Mice Model Market to Reach US$ 3.60 Bn by 2032, Expanding at 9.9% CAGRCoherent Market Insights | Charles River Laboratories, The Jackson Laboratory - industrytoday.co.uk
Charles River Laboratories International, Inc. $CRL Stock Position Lifted by Balefire LLC - MarketBeat
Fragasso Financial Advisors Inc Sells 2,140 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
How Charles River Laboratories’ CFO Transition and Maintained Outlook May Shift Its Investment Story (CRL) - simplywall.st
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 51,622 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Signal Recap: Will ERIE stock hit new highs in YEARQuarterly Portfolio Report & AI Enhanced Market Trend Forecasts - khodrobank.com
Sell Signal: Is Charles River Laboratories International Inc in accumulation or distribution phaseRecession Risk & Real-Time Volume Analysis - خودرو بانک
Argus Research Remains a Hold on Charles River Labs (CRL) - The Globe and Mail
Tech Rally: Will Charles River Laboratories International Inc. benefit from green energy policiesBuy Signal & Comprehensive Market Scan Reports - خودرو بانک
Market Recap: What are the future prospects of Charles River Laboratories International IncRate Cut & Precise Swing Trade Alerts - خودرو بانک
Volume Report: What are the future prospects of Charles River Laboratories International IncPortfolio Return Report & Precise Swing Trade Entry Alerts - خودرو بانک
Charles River Laboratories International (NYSE:CRL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
CEO Moves: Will Charles River Laboratories International Inc. outperform tech stocks2025 Fundamental Recap & Growth Focused Stock Reports - khodrobank.com
MBB Public Markets I LLC Purchases New Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Here’s Why ClearBridge Investments Growth Strategy Closed Out Charles River Laboratories International (CRL) - Yahoo
Value Recap: What is Immuneering Corporation s debt to equity ratioJuly 2025 Patterns & Reliable Intraday Trade Alerts - khodrobank.com
Amundi Sells 53,919 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Goldman Sachs Group Inc. Purchases 800,762 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Institution Moves: Is Ovid Therapeutics Inc. a good ESG investment2025 Risk Factors & Fast Entry Momentum Trade Alerts - خودرو بانک
Charles River Laboratories Announces Chief Financial Officer Transition - BioSpace
Medical device maker Insulet taps industry veteran Flavia Pease as CFO - Reuters
Quarterly Trades: What is the long term forecast for Charles River Laboratories International Inc. stockWeekly Market Summary & Pattern Based Trade Signal System - خودرو بانک
Charles River Laboratories Appoints Michael G. Knell as Interim CFO - citybiz.co
Revenue Check: Will BLFS be affected by tariffsMarket Sentiment Review & Stepwise Trade Signal Implementation - خودرو بانک
Charles River Labs CFO takes job at local medical device giant - The Business Journals
Charles River Laboratories International, Inc. Announces Resignation of Flavia H. Pease, Corporate Executive Vice President from Her Role, Effective September 29, 2025 - MarketScreener
Charles River Laboratories International, Inc. Announces Chief Financial Officer Transition - MarketScreener
Charles River Laboratories (CRL) Appoints Interim CFO Amid Leade - GuruFocus
Charles River Laboratories (CRL) Maintains FY25 Revenue Forecast - GuruFocus
Charles River (CRL) Executive Moves to Insulet as CFO - GuruFocus
Jobs Data: Is Charles River Laboratories International Inc. in a long term uptrend2025 Stock Rankings & Precise Swing Trade Alerts - خودرو بانک
Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for Year 2025 - MarketScreener
Logan Capital Management Inc. Has $1.74 Million Stake in Charles River Laboratories International, Inc. $CRL - MarketBeat
Aug Fed Impact: Whats next for Charles River Laboratories International Inc stock2025 Historical Comparison & Proven Capital Preservation Tips - خودرو بانک
Insider Sell: Is Charles River Laboratories International Inc. forming a breakout pattern2025 Biggest Moves & Community Shared Stock Ideas - خودرو بانک
Baird Adjusts PT on Charles River Laboratories International to $161 From $151, Maintains Neutral Rating - MarketScreener
Can Schneider National Inc scale operations efficiently2025 Stock Rankings & Advanced Swing Trade Entry Plans - خودرو بانک
Travel Stocks: Why is Charles River Laboratories International Inc. stock going upWeekly Earnings Recap & Real-Time Buy Signal Notifications - خودرو بانک
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.74%
자본화:
|
볼륨(24시간):